Goodwin advised Blueprint Medicines on the deal. Blueprint Medicines announced its strategic collaboration with Proteovant Therapeutics that will leverage Proteovant Therapeutics’ artificial intelligence-enhanced targeted protein degradation platform...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here